About hemophilia B
Hemophilia B, also called the Christmas disease, is a blood coagulation disorder due to the deficiency or improper function of factor IX. It is inherited in an X-linked recessive pattern. This disorder is more prevalent in males than in females. Factor replacement therapies, mainly recombinant, are used in the treatment.
Technavio's analysts forecast the global hemophilia B market to grow posting a CAGR of 4.18% over the period 2014-2019.
Covered in this report
The report includes the present scenario and the growth prospects of the global hemophilia B market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of hemophilia B.
Technavio's report, Global Hemophilia B Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as market segmentation and landscape. The report includes a discussion of the key vendors operating in this market.
Technavio Announces the Publication of its Research Report – Global Hemophilia B Market 2015-2019
Technavio recognizes the following companies as the key players in the Global Hemophilia B Market: Baxter, Grifols, Novo Nordisk and Pfizer
Other Prominent Vendors in the market are: Alnylam Pharmaceuticals, Amarna Therapeutics, Asklepios, Biogen, Catalyst Biosciences, CSL Behring, Dimension Therapeutics, Dong-A Socio, Emergent BioSolutions, Kedrion, OPKO Health, rEVO Biologics, Sangamo BioSciences, Spark Therapeutics, Swedish Orphan Biovitrum, and uniQure.
Commenting on the report, an analyst from Technavio’s team said: “Major vendors are entering into strategic alliances for drug development. Strategic alliances, in terms of licensing and collaboration, help vendors co-develop and commercialize drugs in different regions.”
According to the report, prophylactic treatment is fast gaining popularity among physicians and patients. The treatment increases patients' quality of life in terms of physical strength. It also maintains optimum levels of clotting factors, prevent spontaneous bleeding in individuals with hemophilia B, and reduce joint damage and pains.
Further, the report states that the high cost of treatment leads to the discontinuation of therapy by patients, thereby hampering market growth.
Baxter, Grifols, Novo Nordisk and Pfizer, Alnylam Pharmaceuticals, Amarna Therapeutics, Asklepios, Biogen, Catalyst Biosciences, CSL Behring, Dimension Therapeutics, Dong-A Socio, Emergent BioSolutions, Kedrion, OPKO Health, rEVO Biologics, Sangamo BioSciences, Spark Therapeutics, Swedish Orphan Biovitrum, uniQure.